Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
Salomon M. Stemmer(Tel Aviv University), David Geffen(Ben-Gurion University of the Negev), Noa Ben-Baruch(Kaplan Medical Center), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Nicky Liebermann(Clalit Health Services), Margarita Tokar, Amit Itay(Sheba Medical Center), Steven Shak(Genomic Health (United States)), Shulamith Rizel(Rabin Medical Center), Debbie Jakubowski(Genomic Health (United States)), Avital Bareket‐Samish, Beatrice Uziely(Hadassah Medical Center), Michelle Leviov(Haifa Medical Center), Daniela Katz(Assaf Harofeh Medical Center), Mariana Steiner(Sheba Medical Center), Bella Nisenbaum(Meir Medical Center), Ora Rosengarten(Sheba Medical Center), Julie Baron(Genomic Health (United States)), Georgeta Fried(Roche (Switzerland))
Cited by 30
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
|JAMA Oncology|2021|291
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
|Journal of Cachexia Sarcopenia and Muscle|2018|107